$QURE
uniQure N.V.

2021 Q1 Form 10-Q Financial Statement

#000155837021006590 Filed on May 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2020 Q1
Revenue $454.0K $34.09M $104.0K
YoY Change 336.54% 1196.2% -90.85%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.38M $11.21M $9.072M
YoY Change 36.41% 29.15% 12.46%
% of Gross Profit
Research & Development $32.66M $31.68M $26.01M
YoY Change 25.54% 19.59% 26.66%
% of Gross Profit
Depreciation & Amortization $1.860M $2.300M $1.730M
YoY Change 7.51% 32.18% 10.19%
% of Gross Profit
Operating Expenses $45.03M $42.35M $35.09M
YoY Change 28.35% 18.96% 22.66%
Operating Profit -$44.46M -$34.46M
YoY Change 29.0% 25.3%
Interest Expense $1.551M -$6.810M $975.0K
YoY Change 59.08% 0.44% 1.88%
% of Operating Profit
Other Income/Expense, Net $233.0K -$2.050M $339.0K
YoY Change -31.27% 22.75% -2.87%
Pretax Income -$41.34M -$17.12M -$28.00M
YoY Change 47.66% -58.68% 0.82%
Income Tax $213.0K -$16.42M
% Of Pretax Income
Net Earnings -$41.56M -$700.0K -$28.00M
YoY Change 48.42% -98.31% 0.82%
Net Earnings / Revenue -9153.3% -2.05% -26922.12%
Basic Earnings Per Share -$0.91
Diluted Earnings Per Share -$0.91 -$15.65K -$632.3K
COMMON SHARES
Basic Shares Outstanding 45.47M 44.50M 44.25M
Diluted Shares Outstanding 45.47M

Balance Sheet

Concept 2021 Q1 2020 Q4 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $260.8M $244.9M $342.0M
YoY Change -23.74% -35.18% 63.79%
Cash & Equivalents $260.8M $244.9M $342.0M
Short-Term Investments
Other Short-Term Assets $6.886M $3.024M $1.576M
YoY Change 336.93% 304.28% -60.6%
Inventory
Prepaid Expenses $9.186M $4.337M $5.738M
Receivables $5.445M $6.618M $300.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $282.3M $258.9M $349.6M
YoY Change -19.24% -32.61% 63.98%
LONG-TERM ASSETS
Property, Plant & Equipment $33.86M $32.33M $27.74M
YoY Change 22.09% 12.36% -40.35%
Goodwill $518.0K $542.0K $486.0K
YoY Change 6.58% 9.27%
Intangibles $3.361M
YoY Change
Long-Term Investments
YoY Change
Other Assets $18.90M $2.748M $2.900M
YoY Change 551.72% -5.24% 0.0%
Total Long-Term Assets $81.52M $81.48M $64.64M
YoY Change 26.11% 26.48% 15.85%
TOTAL ASSETS
Total Short-Term Assets $282.3M $258.9M $349.6M
Total Long-Term Assets $81.52M $81.48M $64.64M
Total Assets $363.9M $340.4M $414.2M
YoY Change -12.16% -24.13% 53.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.749M $3.772M $4.989M
YoY Change 15.23% -33.6% 42.54%
Accrued Expenses $20.90M $18.04M $9.507M
YoY Change 119.8% 44.8% -14.35%
Deferred Revenue $2.082M $6.732M
YoY Change -72.7%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change
Total Short-Term Liabilities $32.10M $27.33M $27.13M
YoY Change 18.34% -13.58% 21.11%
LONG-TERM LIABILITIES
Long-Term Debt $70.47M $35.62M $36.21M
YoY Change 94.61% -1.23% 1.71%
Other Long-Term Liabilities $3.107M $3.136M $524.0K
YoY Change 492.94% 487.27% -99.03%
Total Long-Term Liabilities $103.1M $69.16M $91.97M
YoY Change 12.06% -26.38% 2.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.10M $27.33M $27.13M
Total Long-Term Liabilities $103.1M $69.16M $91.97M
Total Liabilities $135.2M $96.49M $119.1M
YoY Change 13.49% -23.16% 6.43%
SHAREHOLDERS EQUITY
Retained Earnings -$826.3M -$784.7M -$687.7M
YoY Change 20.15% 18.95%
Common Stock $2.780M $2.711M $2.683M
YoY Change 3.62% 2.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $228.7M $243.9M $295.1M
YoY Change
Total Liabilities & Shareholders Equity $363.9M $340.4M $414.2M
YoY Change -12.16% -24.13% 53.99%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2020 Q1
OPERATING ACTIVITIES
Net Income -$41.56M -$700.0K -$28.00M
YoY Change 48.42% -98.31% 0.82%
Depreciation, Depletion And Amortization $1.860M $2.300M $1.730M
YoY Change 7.51% 32.18% 10.19%
Cash From Operating Activities -$41.27M -$37.18M -$32.95M
YoY Change 25.25% 43.0% 24.64%
INVESTING ACTIVITIES
Capital Expenditures $3.876M -$2.690M $677.0K
YoY Change 472.53% 36.55% 189.32%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$3.876M -$2.690M -$2.890M
YoY Change 34.12% 36.55% 134.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $28.73M $1.010M
YoY Change 2744.95% -53.63%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 62.62M 3.750M 1.010M
YoY Change 6099.8% 186.26% -62.29%
NET CHANGE
Cash From Operating Activities -41.27M -37.18M -32.95M
Cash From Investing Activities -3.876M -2.690M -2.890M
Cash From Financing Activities 62.62M 3.750M 1.010M
Net Change In Cash 15.85M -36.12M -35.78M
YoY Change -144.3% 35.48% 39.61%
FREE CASH FLOW
Cash From Operating Activities -$41.27M -$37.18M -$32.95M
Capital Expenditures $3.876M -$2.690M $677.0K
Free Cash Flow -$45.15M -$34.49M -$33.63M
YoY Change 34.25% 43.53% 26.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5749000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3772000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5457000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5524000
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4602000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2015000
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44777799
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45924729
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001590560
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Trading Symbol
TradingSymbol
QURE
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-36294
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
uniQure N.V.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
P7
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Paasheuvelweg 25
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
1105 BP Amsterdam
CY2021Q1 dei Entity Address Country
EntityAddressCountry
NL
CY2021Q1 dei City Area Code
CityAreaCode
31
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
20-240-6000
CY2021Q1 dei Security12b Title
Security12bTitle
Ordinary Shares, par value €0.05
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46017621
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
260813000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
244932000
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5445000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6618000
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9186000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4337000
CY2021Q1 us-gaap Other Assets Current
OtherAssetsCurrent
6886000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3024000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
282330000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
258911000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
35900000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
35200000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33862000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32328000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25313000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26086000
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2908000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3361000
CY2021Q1 us-gaap Goodwill
Goodwill
518000
CY2020Q4 us-gaap Goodwill
Goodwill
542000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2716000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2748000
CY2021Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
16206000
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
16419000
CY2021Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
81523000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
81484000
CY2021Q1 us-gaap Assets
Assets
363853000
CY2020Q4 us-gaap Assets
Assets
340395000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20896000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18038000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
32102000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27334000
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
70467000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
35617000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29487000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30403000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3107000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3136000
CY2021Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
103061000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
69156000
CY2021Q1 us-gaap Liabilities
Liabilities
135163000
CY2020Q4 us-gaap Liabilities
Liabilities
96490000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45924729
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44777799
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
2780000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2711000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1049850000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1016018000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2347000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
9907000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-826287000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-784731000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
228690000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
243905000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
363853000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
340395000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
454000
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
104000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32656000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26013000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12375000
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9072000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
45031000
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
35085000
CY2021Q1 us-gaap Other Income
OtherIncome
352000
CY2020Q1 us-gaap Other Income
OtherIncome
857000
CY2021Q1 us-gaap Other Expenses
OtherExpenses
233000
CY2020Q1 us-gaap Other Expenses
OtherExpenses
339000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-44458000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-34463000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
40000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
822000
CY2021Q1 us-gaap Interest Expense
InterestExpense
1551000
CY2020Q1 us-gaap Interest Expense
InterestExpense
975000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4626000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-41343000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-27999000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
213000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41556000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27999000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-7560000
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-5277000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49116000
CY2020Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
4824000
CY2021Q1 qure Change In Deferred Tax Expense
ChangeInDeferredTaxExpense
213000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
270000
CY2021Q1 qure Increase Decrease In Accounts Receivable Prepaid Expense And Other Current Assets
IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets
8023000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33276000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.91
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45468485
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44279456
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
323058000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27999000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-5277000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
932000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4355000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
78000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
295147000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
243905000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41556000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-7560000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
27699000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
392000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5761000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
49000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
228690000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-41556000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-27999000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1862000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1733000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5761000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4355000
CY2020Q1 qure Change In Fair Value Of Derivative Financial Instruments And Contingent Consideration
ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration
-2015000
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
5342000
CY2020Q1 qure Increase Decrease In Accounts Receivable Prepaid Expense And Other Current Assets
IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets
1282000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2510000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-546000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3302000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2645000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41273000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32953000
CY2020Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2213000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3876000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
677000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3876000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2890000
CY2021Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
34603000
CY2021Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
28734000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1161000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
442000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2082000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20896000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18038000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1010000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62618000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1010000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1620000
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-943000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15849000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-35776000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
247680000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
380726000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
263529000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
344950000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
260813000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
342029000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2716000
CY2020Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2921000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
263529000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
344950000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
1410000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
780000
CY2021Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">1</b></span>General business information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">uniQure (the “Company”) was incorporated on January 9, 2012 as a private company with limited liability (<i style="font-style:italic;">besloten vennootschap met beperkte aansprakelijkheid</i>) under the laws of the Netherlands. The Company is a leader in the field of gene therapy and seeks to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. The Company’s business was founded in 1998 and was initially operated through its predecessor company, Amsterdam Molecular Therapeutics (AMT) Holding N.V (“AMT”). In 2012, AMT undertook a corporate reorganization, pursuant to which uniQure B.V. acquired the entire business and assets of AMT and completed a share-for-share exchange with the shareholders of AMT. Effective February 10, 2014, in connection with its initial public offering, the Company converted into a public company with limited liability (<i style="font-style:italic;">naamloze vennootschap</i>) and changed its legal name from uniQure B.V. to uniQure N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 1pt 0pt 1pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is registered in the trade register of the Chamber of Commerce (<i style="font-style:italic;">Kamer van Koophandel</i>) in Amsterdam, the Netherlands under number 54385229. The Company’s headquarters are in Amsterdam, the Netherlands, and its registered office is located at Paasheuvelweg 25, Amsterdam 1105 BP, the Netherlands and its telephone number is +31 20 240 6000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s ordinary shares are listed on the Nasdaq Global Select Market and trade under the symbol “QURE”.</p>
CY2021Q1 qure Accruals For Services Provided By Vendors Not Yet Billed Current
AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
11180000
CY2020Q4 qure Accruals For Services Provided By Vendors Not Yet Billed Current
AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
8269000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4716000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7687000
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5000000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.3</b></span><b style="font-weight:bold;">Use of estimates </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p>
CY2021Q1 qure Number Of Warrant Types
NumberOfWarrantTypes
2
CY2021Q1 qure Number Of Collaboration Targets
NumberOfCollaborationTargets
4
CY2021Q1 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2021Q1 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2021Q1 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
15800000
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
400000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0144
CY2021Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
200000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005
CY2021Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.25
CY2020Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021Q1 qure Effective Tax Rate For Dutch Operations
EffectiveTaxRateForDutchOperations
0
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4143357
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13916001

Files In Submission

Name View Source Status
0001558370-21-006590-index-headers.html Edgar Link pending
0001558370-21-006590-index.html Edgar Link pending
0001558370-21-006590.txt Edgar Link pending
0001558370-21-006590-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
qure-20210331.xsd Edgar Link pending
qure-20210331x10q.htm Edgar Link pending
qure-20210331x10q_htm.xml Edgar Link completed
qure-20210331xex10d1.htm Edgar Link pending
qure-20210331xex31d1.htm Edgar Link pending
qure-20210331xex31d2.htm Edgar Link pending
qure-20210331xex32d1.htm Edgar Link pending
qure-20210331_cal.xml Edgar Link unprocessable
qure-20210331_def.xml Edgar Link unprocessable
qure-20210331_lab.xml Edgar Link unprocessable
qure-20210331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending